Aspectos diagnósticos, evolutivos y terapéuticos de la leucemia mieloide crónica

Avila Cabrera, Onel M; Expósito Delgado, Yesi C; González Pinedo, Leslie; Espinosa Estrada, Edgardo; Hernández Padrón, Carlos; Ramón Rodríguez, Luis G; Izquierdo Cano, Lissette; Mustelier Celza, Gelquin; Roque García, Wilfredo; Bencomo Hernández, Antonio.
Rev. cuba. hematol. inmunol. hemoter ; 30(1): 47-58, ene.-mar. 2014. graf
Artículo en Español | CUMED | ID: cum-56345

Documentos relacionados

  1. Clinical applications of abnormal DNA methylation in chronic myeloid leukemia.
  2. Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML).
  3. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
  4. Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy.
  5. Chronic Myeloid Leukemia During Pregnancy with Placental Involvement: Case Report and Literature Review.
  6. Measurable residual disease in chronic myeloid leukemia.
  7. Análisis de la presencia de trisomía 8 en las diferentes fases de leucemia mieloide crónica.
  8. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
  9. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
  10. Improvement, Implementation, and Evaluation of the CMyLife Digital Care Platform: Participatory Action Research Approach.